Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vicinitas Therapeutics, a biotechnology company advancing a proprietary targeted protein stabilization platform to develop novel therapeutics in cancer and genetic disorders, today launched with $65 million in Series A financing. The financing was co-led by a16z and Deerfield Management, with participation from Droia Ventures, GV, The...

Click to view original post